Surfen
Based on 2 publication(s) in Google Scholar
Surfen is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC50 of approximately 2 μM. Surfen inhibits HSV-1 viral infection. Surfen inhibits neural differentiation, delays remyelination, and alleviates EAE.
For research use only. We do not sell to patients.
- CAS No.: 3811-56-1
- Formula: C21H20N6O
- Molecular Weight:372.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Surfen
More
Biological Activity
Description
IC50 & Target
|
FGFR2 5 μM (IC50) |
HSV-1 |
In Vitro
Surfen (3 μM) binds to glycosaminoglycans (GAGs)[1].
Surfen (1 mg) neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins[1].
Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase, with an IC50 of ~2 μM[1].
Surfen (1-≥5 μM) inhibits cell attachment in a dose-dependent manner, and completely inhibits HSV-1 infection in CHO cells[1].
Surfen (5 μM) effectively inhibits neural differentiation and promotes the maintenance of pluripotency in mouse embryonic stem cells (mESCs)[2].
Surfen (2.5-20 μM) reduces the proliferation of murine T cells activated with anti-CD3/CD28 antibody-coated T cell expander beads[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Surfen (5 mg/kg; i.p.; every other day) alleviates clinical symptoms and reduces the infiltration of CD4 positive T cells and macrophages into the central nervous system in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis in mice[5].
Surfen (100 μM; injection into the right burr hole) delays remyelination of the lesions in the Lysolecithin (LPC)-induced demyelination mouse model[5].
Surfen (20 mg/kg; i.p.; daily; 3 consecutive days) inhibits the proliferation of T cells activated by anti-CD3 antibody in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 adult female mice (16-20 g, 6-8 weeks of age), experimental autoimmune encephalomyelitis (EAE) model[5]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection, every other day
-
Result:Significantly reduced clinical scores between days 13-21.
Reduced mean clinical score to 1.96.
Significantly reduced the number of days with a score of 2.5 or above.
Reduced the percentage of CD4 positive T cells and macrophages in the spinal cord and cerebellum, and decreased the mRNA expression of chemokines CCL3 and CCL5 in the spinal cord.
Chemical Information
-
CAS No. 3811-56-1
-
Molecular Weight 372.42
-
Formula C21H20N6O
-
SMILES
O=C(NC1=CC2=C(N=C(C)C=C2N)C=C1)NC3=CC4=C(N=C(C)C=C4N)C=C3
-
Synonyms
Aminoquinuride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Microbiol Spectr
Aminoquinoline surfen inhibits pseudorabies virus attachment by preventing the binding of glycoprotein C to heparan sulfate. [Abstract]2026 Apr 7;14(4):e0322325. PMID: 41784488 -
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
iPSC/hPSC-Derived Neuron Differentiation Culture
iPSC/hPSC-derived neuron differentiation culture directs pluripotent cells toward neuroectoderm and then neuronal lineages by suppressing developmental signals that maintain non-neural fates; the classic monolayer dual-SMAD approach blocks BMP and Activin/TGF-β signaling with Noggin or dorsomorphin/LDN193189 plus SB431542, producing PAX6-positive neural progenitors that can be further matured into neurons. The readout is generated by morphology, neural progenitor markers, neuronal markers, subtype markers, and functional assays: PAX6/SOX1/NESTIN indicate neural progenitor induction, βIII-tubulin/TUJ1 and MAP2 indicate neuronal differentiation, cortical programs can be assessed by FOXG1, TBR1, CTIP2, SATB2, and synaptic maturation can be assessed by synaptic proteins, calcium activity, multielectrode arrays, or patch-clamp electrophysiology.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Human pluripotent stem cell neural induction and neuron differentiation
Human pluripotent stem cell neural induction can be achieved by blocking BMP and TGFβ/Activin/Nodal SMAD signaling, which suppresses non-neural differentiation and promotes early neuroectodermal identity; the expected readout is loss of pluripotency markers such as OCT4 and induction of neural markers such as PAX6, followed by neural progenitor and neuron marker acquisition during differentiation. This protocol uses dual-SMAD neural induction as the core induction method, followed by cortical neuron differentiation as a representative neuron differentiation model; published cortical protocols describe generation of cortical progenitors, temporally ordered cortical projection neurons, action-potential firing, synaptogenesis, and neural network formation over an approximately 80-day process.
-
Cell differentiation
Cell differentiation refers to the process in which cells of the same origin gradually produce cell groups with different morphological structure and functional characteristics.
Purity & Documentation
References
[1]. Schuksz M, et al. Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13075-80. [Content Brief]
[2]. Huang ML, et al. Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells. 2018 Jan;36(1):45-54. [Content Brief]
[3]. Varatharajan A, et al. Visual determination of heparin in serum utilizing surfen-induced aggregation emission enhancement of gold nanoclusters and heparin-induced fluorescence enhancement of surfen. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Apr 15;339:126251. [Content Brief]
[4]. Alavi Naini SM, et al. Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy. Transl Neurodegener. 2018 Mar 16;7:6. [Content Brief]
[5]. Warford JR, et al. Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis. Acta Neuropathol Commun. 2018 Jan 4;6(1):4. [Content Brief]
[6]. Warford J, et al. Murine T cell activation is regulated by surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide). Biochem Biophys Res Commun. 2014 Jan 10;443(2):524-30. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)